Obinutuzumab

證據等級: L5

預測適應症: 3 個

Obinutuzumab: From CD20+ B-Cell Malignancy to Follicular Lymphoma

One-Sentence Summary

Obinutuzumab is a glycoengineered anti-CD20 monoclonal antibody already used against CD20-positive B-cell blood cancers, including chronic lymphocytic leukemia (CLL). The TxGNN model's top actionable prediction extends this activity to Follicular Lymphoma (FL), a closely related B-cell malignancy, and this direction is backed by 50 clinical trials (including the pivotal Phase 3 GALLIUM trial) and 20 publications. The model separately flags two ultra-specific CLL/SLL molecular subtypes with near-identical scores but zero supporting trials or literature in this dataset — likely an ontology-granularity artifact rather than a genuinely unsupported signal.

Quick Overview

Item	Content
Original Indication	Not on file for Finland (drug is unmarketed there; `taiwan_regulatory.licenses` is empty). Trial records in this evidence pack describe obinutuzumab as already approved elsewhere in combination regimens for CLL and, later, FL.
Predicted New Indication	Follicular Lymphoma
TxGNN Prediction Score	99.18%
Evidence Level	L1
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Note on other predictions: TxGNN also ranked two molecularly-defined CLL/SLL subtypes ("pregerminal center CLL/SLL" and "CLL/SLL with IGHV somatic hypermutation") at essentially the same score (~99.2%), but no clinical trials or literature were retrieved for either — evidence level L5, decision stage S0, recommendation Hold. These are treated here as low-priority signals warranting no independent action until better-resolved disease terms allow evidence linkage.

Why is This Prediction Reasonable?

Formal mechanism-of-action data for obinutuzumab is flagged as a data gap (DG002, High severity) in this evidence pack. However, the trial and rationale records that were retrieved consistently describe obinutuzumab as a third-generation, glycoengineered type II anti-CD20 IgG1 monoclonal antibody that produces enhanced antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct B-cell killing compared with rituximab.

Follicular lymphoma, like CLL/SLL, is a CD20-positive B-cell malignancy, so the molecular target obinutuzumab engages is directly expressed on the tumor cells in both diseases. This is not a distant repurposing leap across unrelated organ systems — it reflects the drug's existing mechanistic footprint in indolent B-cell lymphoproliferative disease being extended from one CD20+ malignancy to another.

This mechanistic plausibility is strongly corroborated by real-world development: obinutuzumab (via multiple trial records in this pack, e.g. NCT02877550) is already described as approved in combination with chlorambucil for untreated CLL and in combination with bendamustine for FL. The TxGNN prediction for FL therefore aligns with an indication space the drug has already been extensively studied and, in some markets, approved for — which explains the unusually mature L1 evidence base compared to a typical de novo repurposing candidate.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01332968	Phase 3	Completed	1401	GALLIUM trial: obinutuzumab + chemotherapy vs. rituximab + chemotherapy in untreated advanced indolent NHL, with obinutuzumab or rituximab maintenance in responders — pivotal direct-comparison evidence.
NCT01059630	Phase 3	Completed	413	Bendamustine alone vs. bendamustine + obinutuzumab (GA101) in rituximab-refractory indolent NHL, with obinutuzumab maintenance.
NCT03332017	Phase 2	Completed	217	ROSEWOOD: zanubrutinib + obinutuzumab vs. obinutuzumab monotherapy in relapsed/refractory FL.
NCT03817853	Phase 4	Completed	114	Safety of obinutuzumab given as a short-duration (90-minute) infusion from cycle 2 onward, combined with chemotherapy, in untreated advanced FL.
NCT02611323	Phase 1/2	Completed	133	Obinutuzumab + polatuzumab vedotin + venetoclax in relapsed/refractory FL.
NCT02600897	Phase 1/2	Completed	114	Obinutuzumab + polatuzumab vedotin + lenalidomide in relapsed/refractory FL.
NCT03113422	Phase 2	Completed	56	Venetoclax + obinutuzumab + bendamustine as front-line therapy in high tumor burden FL.
NCT04034056	N/A (observational)	Completed	299	Non-interventional, retrospective/prospective real-world study of obinutuzumab effectiveness and safety in previously untreated advanced FL.
NCT05783596	Phase 2	Active, not recruiting	47	Glofitamab + obinutuzumab for first-line treatment of FL and marginal zone lymphoma.
NCT05058404	Phase 3	Active, not recruiting	605	FIL_FOLL19: shortened vs. standard chemo-immunotherapy for initial treatment of high tumor burden FL.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28976863	2017	RCT	New England Journal of Medicine	Primary GALLIUM report: obinutuzumab-based chemoimmunotherapy compared with rituximab-based chemoimmunotherapy in previously untreated advanced FL.
29856692	2018	RCT	Journal of Clinical Oncology	GALLIUM sub-analysis showing obinutuzumab significantly prolonged progression-free survival vs. rituximab across CHOP/CVP/bendamustine chemotherapy backbones.
37506346	2023	RCT	Journal of Clinical Oncology	ROSEWOOD: zanubrutinib + obinutuzumab vs. obinutuzumab monotherapy in relapsed/refractory FL.
37404773	2023	RCT (final analysis)	HemaSphere	Final GALLIUM results confirming durable PFS benefit of obinutuzumab- vs. rituximab-based immunochemotherapy in untreated FL.
31296423	2019	RCT	The Lancet Haematology	GALEN: obinutuzumab + lenalidomide in relapsed/refractory follicular B-cell lymphoma, single-arm Phase 2.
37767550	2024	Cohort	Haematologica	Phase Ib/II GO29365: polatuzumab vedotin + bendamustine + rituximab or obinutuzumab in relapsed/refractory FL.
40355425	2025	Phase 2 trial	Blood Cancer Journal	PrE0403: intermittent-dose venetoclax added to bendamustine + obinutuzumab as front-line therapy in high-risk FL.
31360086	2017	Review	Blood and Lymphatic Cancer: Targets and Therapy	Review of obinutuzumab alone and in combination for FL, covering mechanism and combination rationale.
38660754	2024	Review	Turkish Journal of Haematology	Comprehensive review of FL staging, prognosis, and current/emerging treatment options including obinutuzumab-based regimens.
28324270	2017	Review	Targeted Oncology	Review of obinutuzumab in rituximab-refractory/relapsed FL, including GADOLIN trial data.

Finland Market Information

Obinutuzumab currently holds no marketing authorization in Finland (market_status: not marketed; total_licenses: 0). No product, dosage form, or approved-indication data is available to report.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — glycoengineered anti-CD20 monoclonal antibody (not conventional cytotoxic chemotherapy)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are all flagged as data gaps in this evidence pack — notably DG001, a Blocking-severity gap on TFDA-equivalent label warnings/contraindications.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The follicular lymphoma prediction is supported by L1-level evidence — most notably the completed Phase 3 GALLIUM trial (n=1401) and its final published analysis — and is mechanistically consistent with obinutuzumab's known anti-CD20 activity in CD20+ B-cell malignancies. However, two Blocking/High-severity data gaps (TFDA-equivalent safety labeling, and formal MOA documentation) must be closed before this can advance past initial safety screening.

To proceed, the following is needed:

TFDA/Fimea package insert warnings and contraindications (DG001, Blocking)
Formal documented mechanism of action (DG002, High)
Confirmation of Finland/Taiwan market authorization pathway, since obinutuzumab currently has zero licenses on file
Route-compatibility and dosing-regimen assessment (currently marked "pending" in the evidence pack)
Re-query of the two CLL/SLL molecular-subtype predictions under broader/parent disease terms to determine whether the current zero-evidence result is a true gap or an ontology-matching artifact
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.